Molecular Mechanisms Underlying the Enhanced Analgesic Effect of Oxycodone Compared to Morphine in Chemotherapy-Induced Neuropathic Pain

Thibault, Karine; Calvino, Bernard; Rivals, Isabelle; Marchand, Fabien; Dubacq, Sophie; McMahon, Stephen B.; Pezet, Sophie

doi:10.1371/journal.pone.0091297

Cited by 47 publications

(28 citation statements)

References 48 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a recent study on vincristine-induced peripheral neuropathic pain rats, both oxycodone and morphine as a single injection attenuated allodynia and hyperalgesia, but oxycodone was more potent on static mechanical hyperalgesia and dynamic mechanical hyperesthesia. Moreover, oxycodone maintained a significant analgesic efficacy after repeated doses, but multiple morphine injections led to an attenuation of analgesic efficacy [119]. Supporting data on the superiority of oxycodone was observed in a mouse femur bone cancer model.…”

Section: Oxycodone In Neuropathic Painmentioning

confidence: 59%

Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone

et al. 2019

View full text Add to dashboard Cite

Global oxycodone consumption has increased sharply during the last two decades, and, in 2008, oxycodone consumption surpassed that of morphine. As oxycodone was synthesized in 1916 and taken to clinical use a year later, it has not undergone the same approval process required by today's standards. Most of the basic oxycodone pharmacokinetic (PK) data are from the 1990s and from academic research; however, a lot of additional data have been published over the last 10 years. In this review, we describe the latest oxycodone data on special populations, including neonates, children, pregnant and lactating women, and the elderly. A lot of important drug interaction data have been published that must also be taken into account when oxycodone is used concomitantly with cytochrome P450 (CYP) 3A inducers and inhibitors and/or CYP2D6 inhibitors. In addition, we gathered data on abuse-deterrent oxycodone formulations, and the PK of alternate administration routes, i.e. transmucosal and epidural, are also described. Mari Kinnunen and Panu Piirainen contributed equally to this work.

show abstract

Section: Oxycodone In Neuropathic Painmentioning

confidence: 59%

Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone

et al. 2019

View full text Add to dashboard Cite

show abstract

“…antinociception in acute and chronic pain (13,14). A study by Thibault et al (15) reported that the GABAB receptor is functionally required for the alleviating effect of oxycodone in vincristine-induced neuropathic pain. The analgesic effect of fucoidan on vincristine-induced neuropathic pain may be associated with its upregulation of the expression of GABAB receptor.…”

Section: Effects Of Repeated Fucoidan Administration On the Expressiomentioning

confidence: 99%

Antinociceptive effects of fucoidan in rat models of vincristine-induced neuropathic pain

Zhao

Zhang

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

Chemotherapeutic drugs commonly induce peripheral neuropathic pain, which limit their clinic use. In the present study, the effect of fucoidan on the development of vincristine‑induced neuropathic pain was evaluated and the underlying mechanism was examined. A neuropathy model was established in Sprague‑Dawley rats by intraperitoneal injection of vincristine sulfate 50 µg/kg once a day for 10 consecutive days. Fucoidan (50, 100 or 200 mg/kg.) and pregabalin (10 mg/kg) were injected for 14 consecutive days. Behavioral assessments were then performed and the expression of GABAB receptor was determined. The results showed that a single treatment with fucoidan did not prevent the induction of vincristine‑induced mechanical or cold allodynia. However, repeated fucoidan administration attenuated vincristine‑induced mechanical and cold allodynia in a dose‑dependent manner. Additionally, the analgesic effects of fucoidan contributed to an upregulation in the expression of GABAB receptor in the spinal cord. Furthermore, all the effects of fucoidan against vincristine‑induced neuropathy were reversed by saclofen, a selective GABAB receptor antagonist. These results suggested that the antinociceptive effects of fucoidan may be through activation of GABAB receptor, and fucoidan may be a promising drug for the treatment of chemotherapeutic drug-induced neuropathic pain.

show abstract

“…Several studies have reported that oxycodone is a potent neuropathic pain reliever through up‐regulating expression of GABA B receptor in sensory neurons; in contrast, this type of pain is unaffected by the action of morphine.…”

Section: Discussionmentioning

confidence: 99%